Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate

American Journal of Respiratory and Critical Care Medicine

Volumn 153, Issue 3, 1996, Pages 924-930

  Bootsma, Gerben P ^a   Dekhuijzen, P N Richard ^b   Festen, Jan ^b   Mulder, Paul G H ^b   Swinkels, Leon M J W ^b   Van Herwaarden, Cees L A ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; FLUTICASONE PROPIONATE;

ADULT; ARTICLE; ASTHMA; BONE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG POTENCY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029972709     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.153.3.8630574     Document Type: Article

References (33)

1. National Heart Lung and Blood Institute. 1992. International consensus report on diagnosis and treatment of asthma. Eur. Respir. J. 5:601-641.
2. Guidelines on the management of asthma. 1993. Thorax 48(Suppl.): S1-S24.
3. Barnes, P. J., and S. Pedersen. 1993. Efficacy and safety of inhaled corticosteroids in asthma. Am. Rev. Respir. Dis. 148(Suppl.):S1-S26.
4. English, A. F., M. S. Neate, D. J. Quint, and M. Sareen. 1994. Biological activities of some corticosteroids used in asthma (abstract). Am. J. Respir. Crit. Care Med. 149:A212.
5. Leblanc, P., S. Mink, T. Keistinen, P. A. Saarelainen, N. Ringdal, and S. L. Payne. 1994. A comparison of fluticasone propionate 200 μg/day with beclomethasone dipropionate 400 μg/day in adult asthma. Allergy 49:380-385.
6. Barnes, N. C., G. Marone, G. U. DiMaria, S. Visser, I. Utama, and S. L. Payne, on behalf of an international study group. 1993. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. Eur. Respir. J. 6:877-884.
7. Bootsma, G. P., P. N. R. Dekhuijzen, J. Festen, P. G. H. Mulder, and C. L. A. van Herwaarden. 1995. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Thorax 50:1044-1050.
8. Harding, S. M. 1990. The human pharmacology of fluticasone propionate. Respir. Med. 84(Suppl. A):25-29.
9. Toogood, J. H. , R. G. Crittly, G. Jones, J. Nadeau, and G. A. Wells. 1988. Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis. Am. Rev. Respir. Dis. 138:57-61.
10. Ali, N. J., S. Capewell, and M. J. Ward. 1991. Bone turnover during high dose inhaled corticosteroid treatment. Thorax 46:160-164.
11. Pouw, E. M., M. F. Prummel, H. Oosting, C. M. Roos, and E. Endert. 1991. Beclomethasone inhalation decreases serum osteocalcin concentrations. B.M.J. 302:627-628.
12. Hodsman, A. B., J. H. Toogood, B. Jennings, L. H. Fraher, and J. C. Baskerville. 1991. Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin. J. Clin Endocrinol. Metab. 72: 530-540.
13. Jennings, B. H., K.-E. Andersson, and S. Å. Johansson. 1991. Assessment of systemic effects of inhaled glucocorticosteroids: comparison of effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur. J. Clin. Pharmacol. 40:77-82.
14. Teelucksing, S., P. L. Padfield, L. Tibi, K. J. Gough, and P. R. Holt. 1991. Inhaled corticosteroids, bone formation, and osteocalcin. Lancet 138:60-61.
15. Ristelli, L., and J. Ristelli. 1993. Biochemical markers of bone metabolism. Ann. Med. 25:385-393.
16. Taylor, A. K., S. A. Leuken, C. Libanati, and D. J. Baylink. 1994. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. In N. E. Lane, editor. Rheumatic Disease Clinics of North America. W. B. Saunders, Philadelphia. 20:589-607.
17. 47Ca-kinetics: efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase and urinary hydroxyproline excretion. J. Clin. Invest. 76:2254-2258.
18. Van Hoof, H. J. C., L. M. J. W. Swinkels, J. J. van Stevenhage, H. van den Berg, H. A. Ross, and Th. J. Benraad. 1993. Advantages of paper chromatography as a preparative step in the assay of 1,25-dihydroxyvitamin D. J. Chromatogr. 621:33-39.
19. Jones, B., and M. G. Kenward. 1989. Design and analysis of cross-over trials, 1st ed. Chapman and Hall, London. 16-88.
20. Adinoff, A. D., and J. R. Hollister. 1983. Steroid-induced fractures and bone loss in patients with asthma. N. Engl. J. Med. 309:265-268.
21. Reid, I. R. 1989. Pathogenesis and treatment of steroid osteoporosis. Clin. Endocrinol. (Oxford) 30:83-103.
22. Oikarinen, A., P. Autio, J. Vuori, K. Väänänen, L. Ristelli, U. Kiistala, and J. Ristelli. 1992. Systemic glucorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. Br. J. Dermatol. 126:172-178.
23. Morrisson, D., N. J. Ali, P. A. Routledge, and S. Capewell. 1992. Bone turnover during short course prednisolone treatment in patients with chronic obstructive airways disease. Thorax 47:418-420.
24. Worth, H., D. Stammen, and E. Keck. 1994. Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and diphosphanate. Am. J. Respir. Crit. Care Med. 150:394-397.
25. Lukert, B. P., and L. G. Raisz. 1990. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann. Intern. Med. 112:352-364.
26. Kerstjens, H. A. M., D. S. Postma, J. J. van Doormaal, A. K. van Zanten, P. L. P. Brand, P. N. R. Dekhuijzen, and G. H. Koëter, on behalf of the Dutch CNSLD Study Group. 1994. Effects of short term and long term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Thorax 49:652-656.
27. Packe, G. E., J. G. Douglas, A. F. McDonald, S. P. Robins, and D. M. Reid. 1992. Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax 47:414-417.
28. Sorva, R., R. Tähtelä, M. Turpeinen, K. Juntunen-Backman, and T. Haahtela. 1994. Bone turnover during inhaled budesonide (BUD) in childhood asthma. Allergy Clin. Immunol. News 6(Suppl. 2):21.
29. Nicolaizik, W. H., J. L. Marchant, M. A. Preece, and J. O. Warner. \1994. Endocrine and lung function in asthmatic children receiving inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 150:624-628.
30. Kiviranta, K., and M. Turpeinen. 1993. Effect of eight months of inhaled beclomethasone dipropionate and budesonide on carbohydrate metabolism in adults with asthma. Thorax 48:974-978.
31. Consensus Development Conference report. 1991. Prophylaxis and treatment of osteoporosis. Am. J. Med. 90:107-110.
32. Stepan, J. J., J. Pospichal, J. Presl, and V. Pacovsky. 1987. Bone loss and biochemical indices of bone remodeling in surgically induced post-menopausal women. Bone 8:279-284.
33. Ip, M., K. Lam, L. Lam, A. Kung, and M. Ng. 1994. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 105:1722-1727.